deListed Australia
 
SEARCH LISTED OR DELISTED COMPANY
Any AUS or NZ company

Browse Australian delisted companies

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Browse terminated Australian managed funds

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
SEARCH PRIVATE COMPANY
SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

NOVOGEN LIMITED (ASX.NRT)

ASX, Legal & CGT Status

SHARE PRICES

(updated at weekends)
Former (or subsequent) names
CompanyFROMTO
KAZIA THERAPEUTICS LIMITED29/11/2017
NOVOGEN LIMITED13/05/199729/11/2017
NORVET LIMITED13/05/1997
Shareholder links
Our website ranking of NRT: rating 4
(4 out of 5)
COMPANY WEBSITE:

 

REGISTRY:
Computershare Sydney
Level 3, 60 Carrington Street, Sydney NSW 2000
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 2 8235 8150
RegistryWebsite RegistryEmail

Company details
Address: Level 5, 20 George St, Hornsby, NSW, 2077
Tel:  + 61 2 9476 0344 Fax: + 61 2 9476 0388

Date first listed: 01/09/1994
Company Secretary: Kate Hill

Sector: Pharmaceuticals & Biotechnology
Industry Group: XHJ
Activities: Pharmaceutical company involved in the discovery, development, manufacture and marketing of products based on phenolic technology

name changed to Kazia Therapeutics Limited

29/11/2017

we understand that on or about this date the company consolidated its shares 1 for 10

24/11/2017

The suspension of trading in the securities of Novogen Limited (the "Company") will be lifted immediately, following the Company's announcement in relation to the completion of a capital raising. Security Code: NRT

12/11/2014

the Closing Date of its current capital raising using the ASX BookBuild Facility has been extended from today Friday 7 November 2014 at 3 pm, to next Tuesday 11 November 2014

07/11/2014

has received confirmation that its experimental drug product, Cantrixil, has passed its final pre-clinical test of efficacy as evidence of its potential to significantly improve the survival prospects of patients with late-stage ovarian cancer

06/11/2014

The securities of Novogen Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement in relation to a placement. Security Code: NRT

05/11/2014

we understand that on or about this date the company made an in specie distribution of 3 shares in MEI Pharma, Inc for every 40 shares in the company

27/11/2012

name changed from Norvet Limited

13/05/1997

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates
Post your comments here
Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box. If an image appears, enter the word/figures you see in the image.

    loading Posting your comments. Please wait...

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNATURENUMBERPRICEAMOUNT
    27/06/2017Bryce Carmine600,000$0.049$29,400
    14/06/2017Iain Ross1,000,000$0.055$55,005
    13/06/2017Steven Coffey320,000$0.057$18,240
    13/06/2017James Garner125,000$0.057$7,125
    24/02/2017Steven Coffey100,000$0.086$8,550

    Click here for the last 20 transactions all companies

    Directors & Executives (current)
    NAMETITLEDATE OF APPT
    Iain RossNon Exec Chairman22/07/2015
    Mark HinzeCFO18/06/2010
    Steven CoffeyNon Exec Director08/11/2012
    Bryce CarmineNon Exec Director03/06/2015
    James GarnerExecutive Director, CEO01/02/2016

    Date of first appointment, title may have changed.

    Directors & Executives (former)
    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    John O'ConnorNon Exec Chairman25/05/201208/06/2017
    Ian PhillipsNon Exec Director03/06/201508/06/2017
    Peter GunningNon Exec Director04/03/201405/09/2016
    Christopher CoxExecutive Director, CEO07/12/201222/07/2015
    Robert BirchDeputy Chairman, Non Exec Director12/12/201204/03/2014
    Andrew HeatonExecutive Director07/12/201204/03/2014
    Josiah AustinNon Exec Director20/09/201019/04/2013
    William RueckertChairman23/03/200907/12/2012
    Peter WhiteNon Exec Director20/09/201007/12/2012
    Ross YoungmanNon Exec Director20/09/201008/11/2012
    Peter ScuttNon Exec Director29/10/201025/05/2012
    Geoffrey LeppinusNon Exec Director24/02/200529/10/2010
    Philip JohnstonNon Exec Chairman01/01/199718/10/2010
    Christopher NaughtonManaging Director, CEO01/03/199701/12/2009

    Date of first appointment, title may have changed.